Saram ConsultingGxP & AI Consulting for Life Sciences. Custom AI integrations, Part 11 compliance validation, and equity-based engineering partnerships for biotech.Explore Services at saram.io →
← Back to Home

Beam Therapeutics

NASDAQ: BEAM ↗$24.34 USD~$4B MCAP
#Genetic Medicines#Hematology#Rare Disease

Biotechnology company pioneering CRISPR base editing to create a new class of precision genetic medicines for serious diseases, including sickle cell disease and alpha-1 antitrypsin deficiency.

Company Info

Sector:Biotechnology
Headquarters:Cambridge, Massachusetts, USA
Founded:2017
Website:beamtx.com/

Clinical Development Pipeline

risto-cel (BEAM-101)

Target: HBG1/HBG2 promoter (fetal hemoglobin upregulation)
Severe sickle cell disease
Preclinical
Phase 1
Phase 2
Phase 3
Approved

BEAM-302

Target: SERPINA1
Alpha-1 antitrypsin deficiency
Preclinical
Phase 1
Phase 2
Phase 3
Approved

BEAM-301

Target: G6PC
Glycogen storage disease type Ia
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Recent News

Leadership Team

John Evans

Chief Executive Officer

Sravan Emany

Chief Financial Officer

J. Keith Joung

Founder

Careers & Job Openings

See all open roles

All
Cambridge, Massachusetts, USA
Apply Now →